TUSTIN, Calif.
(Map)
-
TUSTIN, Calif., Nov. 19 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL),
headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and
Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc.
(JPI), an international biopharma company, announced today that it generated
sales of approximately $5.8 million for the third quarter of 2007 compared to
$2.3 million for the second quarter of 2007. Net income for the third quarter
was approximately $630,000 (unaudited) or $0.05 cents per share, which
includes approximately $250,000 of gain on foreign currency translation. The
results for the three months ended September 30, 2007 reflect the first
quarter of profitable operations since the Company's inception.
Mr. Gary Dreher, CEO of AMDL, noted that, "AMDL's introduction of new
products and increased distribution channels caused the upturn in revenues
demonstrates that JPI should continue to provide earnings in the future. We
anticipate that our Chinese subsidiaries will continue to experience strong
sales and gross profit growth that will greatly improve AMDL's combined
operating results."
About AMDL: More information about AMDL and its products can be obtained
at http://www.amdl.com. AMDL, together with Jade, engages in the development,
manufacture and marketing of proprietary pharmaceutical and diagnostic
products.
About Jade: Jade has access to the fastest growing pharmaceutical and
consumer market in the world: China. AMDL, through its Jade subsidiaries,
currently holds licenses for 133 products that are manufactured as large
volume injection fluids, tablets and other related products. It currently
manufactures over 20 key generic, over the counter and supplemental
pharmaceutical products under certified Chinese Good Manufacturing Practice
(CGMP) standards.
Forward-Looking Statements: This news release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from those
projected in such forward-looking statements. The Company cautions readers not
to place undue reliance on any forward-looking statements. The Company does
not undertake, and specifically disclaims any obligation, to update or revise
such statements to reflect new circumstances or unanticipated events as they
occur.
Contact: AMDL, Inc.
Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
Voice Mail: 714.505.4460
For Immediate Release
